ArcticZymes Technologies ASA (B4V) Price & Analysis
B4V Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 98.24M
- Enterprise Value
- CHF 775.98M
- Total Cash (Recent Filing)
- CHF 242.70M
- Total Debt (Recent Filing)
- CHF 7.95M
- Price to Earnings (P/E)
- 71.3
- Beta
- -0.43
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
ArcticZymes Technologies ASA News
B4V FAQ
What is ArcticZymes Technologies ASA’s market cap?
When is ArcticZymes Technologies ASA’s upcoming earnings report date?
How were ArcticZymes Technologies ASA’s earnings last quarter?
Is ArcticZymes Technologies ASA overvalued?
Does ArcticZymes Technologies ASA pay dividends?
What is ArcticZymes Technologies ASA’s EPS estimate?
How many shares outstanding does ArcticZymes Technologies ASA have?
What happened to ArcticZymes Technologies ASA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ArcticZymes Technologies ASA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ArcticZymes Technologies ASA
ArcticZymes Technologies ASA is a leading life sciences firm dedicated to the development, production, and global sale of recombinant enzymes. These specialized enzymes are essential for a variety of applications, including molecular research, in vitro diagnostic testing, and processes within biomanufacturing. The company's diverse product lineup includes several key enzymatic solutions. For example, its salt active nuclease is instrumental in eliminating nucleic acids during the manufacturing of viral vectors, recombinant proteins, and other critical reagents. ArcticZymes also supplies shrimp alkaline phosphatase and accompanying kits, which are vital for purifying samples before both Sanger and next-generation sequencing. Another significant product is cod UNG, frequently utilized in viral and other molecular diagnostic assays, alongside double-strand specific DNases and their related kits, engineered for the efficient removal of double-stranded DNA. The firm's polymerases are designed to drive technological progress in life science, molecular diagnostics, NGS, and synthetic biology. Furthermore, it offers proteinase for applications in microbiological diagnostics and liquid biopsies, and ligases, which are crucial for connecting DNA and RNA fragments. ArcticZymes Technologies boasts a broad international presence, serving markets in Norway, Germany, Lithuania, Italy, various other European nations, the United States, and additional global territories. Founded in 1990, the enterprise was initially known as Biotec Pharmacon ASA until June 2020, when it officially rebranded to its current name. Its corporate headquarters are located in Tromsø, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Benjamin Akoh
- Employees
- 54
- Website
- arcticzymes.com
- Address
- Sykehusveien 23, Tromsø, TR, 9294, NO